View this API's:

Patents at Patent & Trademark Office Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S14 & S15 NDA 21-039/S13 & S14 10/2/02 10/11/01 10/3/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S11 NDA 21-039/S10 8/2/02 8/6/02 8/5/02 Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S10, & 13 NDA 21-039/S9 & 12 2/5/02 4/17/02 Agenerase (amprenavir) Capsules and Solution, 50mg, 150mg Glaxo Wellcome NDA 21-007 NDA 21-039 4/15/99 7/24/02 5/25/99 7/24/02 Agenerase Indication: for the treatment of HIV-1 infection. Agenerase (amprenavir) Capsules and Solution, GlaxoSmithKline NDA 21-007/S6 NDA 21-039/S6 Agenerase (amprenavir) Capsules and Oral Solution, GlaxoSmithKline   For the latest approval information, locate this drug using this index.